Pristiq news from FierceBiotech
NewsFDA OKs Wyeth's antidepressant Pristiq
Wyeth announced late Friday that it won FDA approval for Pristiq, its next-generation version of the antidepressant Effexor. Wyeth was looking for an approval of Pristiq to offset the Read more...
Wyeth presents Pristiq data
Wyeth is revealing more Pristiq data today from two Phase III clinical studies of Pristiq. Earlier this year, the Read more...
Wyeth's Pristiq shows benefits in clinical trial
Wyeth says that the nonhormonal desvenlafaxine, or Pristiq, demonstrated significant efficacy against hot flashes and night sweats in a clinical trial--but noted that high blood pressure and other Read more...
FDA demands more data on Wyeth's Pristiq
Wyeth was effectively stiff-armed by the FDA in its application for Pristiq, the first non-hormonal therapy to treat menopausal symptoms. In an approvable letter, regulators told the company that Read more...
| Press ReleasesPRESS RELEASE: Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo COLLEGEVILLE, Pa., Oct. 15 -- Wyeth Pharmaceuticals, a Read more... |
Get more Pristiq coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets